# A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

> **NCT03843359** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 97 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** GSK3745417
- **DRUG:** Dostarlimab

## Key facts

- **NCT ID:** NCT03843359
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-12
- **Primary completion:** 2024-04-04
- **Final completion:** 2026-03-31
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03843359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03843359, "A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03843359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*